News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Iframe sync Post navigation Previous: EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories Brain Clinical Trial Disability Hospitals News Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients Staff December 18, 2025 Healthcare Hospitals Neurology News Pharmaceutical BC Platforms and GeneVault partner to unlock access to large-scale real-world and genomic data from under-represented populations Staff December 18, 2025 Healthcare News Pharmaceutical EPS Corporation Selects ArisGlobal’s LifeSphere® MultiVigilance Staff December 18, 2025
